Bayer Pre-Tax Profit Margin 2010-2024 | BAYRY

Current and historical pre-tax profit margin for Bayer (BAYRY) from 2010 to 2024. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Bayer pre-tax profit margin for the three months ending September 30, 2024 was .
Bayer Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2024-09-30 $50.61B $-1.82B -3.60%
2024-06-30 $50.91B $-1.72B -3.37%
2024-03-31 $51.06B $-1.74B -3.41%
2023-12-31 $51.56B $-1.76B -3.40%
2023-09-30 $50.77B $-2.90B -5.71%
2023-06-30 $50.88B $2.38B 4.68%
2023-03-31 $52.48B $3.54B 6.75%
2022-12-31 $53.46B $4.92B 9.20%
2022-09-30 $54.11B $5.99B 11.06%
2022-06-30 $54.28B $5.61B 10.34%
2022-03-31 $53.72B $3.30B 6.14%
2021-12-31 $52.15B $2.42B 4.64%
2021-09-30 $51.58B $2.09B 4.06%
2021-06-30 $49.99B $-9.14B -18.27%
2021-03-31 $47.98B $-18.45B -38.44%
2020-12-31 $47.29B $-19.70B -41.66%
2020-09-30 $45.33B $-21.43B -47.27%
2020-06-30 $46.32B $-9.28B -20.02%
2020-03-31 $48.16B $3.41B 7.08%
2019-12-31 $48.77B $3.23B 6.61%
2019-09-30 $51.32B $-2.33B -4.54%
2019-06-30 $51.90B $0.87B 1.68%
2019-03-31 $50.30B $1.59B 3.17%
2018-12-31 $46.75B $2.74B 5.85%
2018-09-30 $38.16B $8.54B 22.38%
2018-06-30 $36.07B $5.34B 14.81%
2018-03-31 $38.18B $6.04B 15.81%
2017-12-31 $39.58B $5.17B 13.07%
2017-09-30 $48.12B $5.74B 11.93%
2017-06-30 $51.26B $6.28B 12.26%
2017-03-31 $51.21B $6.42B 12.54%
2016-12-31 $51.75B $6.51B 12.58%
2016-09-30 $51.22B $6.72B 13.13%
2016-06-30 $50.93B $6.46B 12.68%
2016-03-31 $50.94B $6.11B 11.99%
2015-12-31 $51.44B $5.82B 11.32%
2015-09-30 $53.15B $5.24B 9.86%
2015-06-30 $54.39B $5.23B 9.62%
2015-03-31 $55.36B $5.31B 9.58%
2014-12-31 $56.15B $6.02B 10.71%
2014-09-30 $55.81B $6.66B 11.94%
2014-06-30 $55.06B $6.55B 11.90%
2014-03-31 $54.25B $6.16B 11.35%
2013-12-31 $53.34B $5.59B 10.48%
2013-09-30 $52.64B $5.52B 10.48%
2013-06-30 $51.96B $5.03B 9.69%
2013-03-31 $51.51B $4.35B 8.45%
2012-12-31 $51.14B $4.18B 8.17%
2012-09-30 $50.72B $4.03B 7.95%
2012-06-30 $50.90B $4.44B 8.72%
2012-03-31 $51.14B $5.32B 10.40%
2011-12-31 $50.83B $4.68B 9.22%
2011-09-30 $50.85B $3.75B 7.37%
2011-06-30 $49.64B $2.88B 5.80%
2011-03-31 $48.04B $2.24B 4.67%
2010-12-31 $46.14B $2.29B 4.95%
2010-09-30 $45.03B $2.87B 6.38%
2010-06-30 $45.05B $3.05B 6.77%
2010-03-31 $44.25B $3.09B 6.99%
2009-12-31 $43.60B $2.61B 5.98%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $22.242B $51.553B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $763.326B 79.06
Novo Nordisk (NVO) Denmark $377.087B 27.19
Johnson & Johnson (JNJ) United States $363.912B 15.13
AbbVie (ABBV) United States $309.709B 16.30
Merck (MRK) United States $248.613B 16.52
Roche Holding AG (RHHBY) Switzerland $247.847B 0.00
AstraZeneca (AZN) United Kingdom $217.852B 18.54
Novartis AG (NVS) Switzerland $210.389B 13.98
Pfizer (PFE) United States $150.855B 10.32
Sanofi (SNY) $132.349B 11.99
Innoviva (INVA) United States $1.183B 9.84